We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Interim Results from Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

News   Dec 10, 2013

 
Interim Results from Phase I/II Trial of Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
 
 
Advertisement
 

RELATED ARTICLES


Converting Autoimmunity Drugs Into Powerful Anticancer Treatments

News

A team from the University of Southampton has discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.

READ MORE

Stopping "Cytokine Storms" May Reduce Severe COVID-19 Symptoms

News

A clinical trial in people with COVID-19 is testing a drug that may halt an overactive immune response known as "cytokine storms" before it ramps up.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE